Compare Adaptive Biotechnologies Corp (ADPT) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares China Large-Cap ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while iShares China Large-Cap ETF trades at $35.41. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | FXI | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $41.75 |
52-Week Low | $12.30 | $31.59 |
Enterprise Value | $4.10B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
